Drawing based on the description in the official product monograph. No photo yet.
“6 . DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. . Table 1 -. Dosage Forms, Strengths,. Composition and Packaging Route of Dosage Form / Non-medicinal Ingredients Administration Strength/Composition Edible black ink, FD&C yellow 6, gelatin, iron oxide red, iron oxide yellow, lactose, Oral Capsules 25 mg magnesium stearate, sodium lauryl sulfate, starch, talc, titanium dioxide DANTRIUM CAPSU”
Dantrium 25 mg 0149 0030 pill
Pill with imprint Dantrium 25 mg 0149 0030 is black & yellow, capsule and has been identified as Dantrolene Sodium 25 mg. It is used for multiple sclerosis and muscle stiffness (spasticity). It is supplied by Knight Therapeutics Inc.
Sold in Canada
Dantrolene Sodium 25 mg
- Brand
- Dantrium Capsules
- Imprint
- Dantrium 25 mg 0149 0030
- Strength
- 25 mg
- Used for
- Multiple sclerosis and muscle stiffness (spasticity)
- Color
- Black, Yellow
- Shape
- Capsule / oblong
- Form
- Capsule
- Manufacturer
- Knight Therapeutics Inc
- Drug class
- Muscle relaxant
- Sold in
- Canada
- DIN
- 01997602
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Dantrolene Sodium used for?
Dantrolene Sodium is used for multiple sclerosis and muscle stiffness (spasticity).
- Medicine type
- Muscle relaxant
Official uses from the US prescribing label
In Chronic Spasticity:
Dantrolene sodiumis indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodiumis not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium.
Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodiumtherapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodiumfor a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.
A decision to continue the administration of dantrolene sodiumon a long-term basis is justified if introduction of the drug into the patient's regimen:
produces a significant reduction in painful and/or disabling spasticity such as clonus, or
permits a significant reduction in the intensity and/or degree of nursing care required, or
rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
In Malignant Hyperthermia:
Oral dantrolene sodiumis also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ®(dantrolene sodium) Intravenous.
Oral dantrolene sodiumshould be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
From the FDA-approved label on DailyMed (published Sep 23, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows Dantrium 25 mg 0149 0030. The parts can be split between the two sides, so turn the pill over and check both.
- It is black & yellow, capsule.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Dantrium Capsules by Knight Therapeutics Inc..
In Canada: prescription only.
Ingredients
Active: Dantrolene Sodium
Other pills with imprint DANTRIUM 25 mg 0149 0030
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
RDY 399
Lansoprazole 30 mg
Black & pink, capsule, 19 mm
Used for acid reflux (GERD) and ulcers
-
barr 033
Chlordiazepoxide Hydrochloride 10 mg
Black & green, capsule, 14 mm
Used for anxiety and alcohol withdrawal
Schedule IV
- LNP200 NVR Iptacopan Hydrochloride 200 mg Black & yellow, capsule Used for paroxysmal hemoglobinuria
- NIT 100 Nitrofurantoin 100 mg Black, capsule Used for urinary tract infections (UTIs) and escherichia coli infections
- HU 500 Hydroxyurea 500 mg Black & pink, capsule Used for psoriasis and prostate cancer
- HP551 HP551 Trientine Hydrochloride 250 mg Black & red, capsule Used for hepatolenticular degeneration and nervous system heavy metal poisoning
Other Dantrolene Sodium pills
-
G443 G443
Dantrolene Sodium 100 mg
Red & yellow, capsule, 19 mm
Used for multiple sclerosis and muscle stiffness (spasticity)
-
G441
Dantrolene Sodium 25 mg
Green & yellow, capsule, 16 mm
Used for multiple sclerosis and muscle stiffness (spasticity)
-
G441 G441
Dantrolene Sodium 25 mg
Green & yellow, capsule, 16 mm
Used for multiple sclerosis and muscle stiffness (spasticity)
-
G442 G442
Dantrolene Sodium 50 mg
Blue & yellow, capsule, 18 mm
Used for multiple sclerosis and muscle stiffness (spasticity)
- DANTRIUM 50 mg 0149 0031 Dantrolene Sodium Brown & orange, capsule, 18 mm Used for multiple sclerosis and muscle stiffness (spasticity)
- DANTRIUM 100 mg 0149 0033 Dantrolene Sodium Brown & orange, capsule, 20 mm Used for multiple sclerosis and muscle stiffness (spasticity)
- A 221 Dantrolene Sodium 100 mg Orange & yellow, capsule, 16 mm Used for multiple sclerosis and muscle stiffness (spasticity)